huberman semaglutide Insights Andrew Huberman clarifies he is

Although experimental studies suggest potential pancreatic harm from GLP-1 RAs, robust clinical evidence demonstrates that these drugs do not increase the incidence of pancreatitis or pancreatic cancer in diverse human populations

Do not use if product has been frozen

Fralick M, Schneeweiss S, Patorno E (2017) Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor

These small steps can help lower the chances of a semaglutide injection site reaction and make your weekly injection easier to handle

11 (2), e9302

Semaglutide is a GLP-1 receptor agonist studied for its effects on appetite suppression, glucose regulation, and insulin sensitivity